The companies said the COVID-19 vaccine generated levels of antibodies that were similar to those of younger adults, meeting the study’s measurements of success.
The companies said the COVID-19 vaccine generated levels of antibodies that were similar to those of younger adults, meeting the study’s measurements of success.